New this week in the nonspecialty journals: Tattoos and sarcoidosis, oral ulcers and autoimmunity, gout and heart disease, and a review about a gene that affects autoimmune inflammation.

The interleukin-1 inhibitor dampened the bouts of pain by more than 70% for gout patients as they begin urate-lowering treatment in the international PRESURGE-2 trial.

They may be supported by guidelines and commonly used in practice, but joint injections with glucocorticoids for acute gout are not backed by any randomized controlled clinical trials, according to a new Cochrane report. However, the report backs away from saying they should not be used.

A series of studies using functional MRI have identified brain-signal patterns specific for pain that are attenuated by opioids: Also last week: top rheumatology findings of 2012, more on TNF inhibitors and cancer, and concerns about vitamin D.

The RADAI joint index designed for rheumatoid arthritis patients provides equally powerful information about disease status in osteoarthritis and psoriatic arthritis, according to a new comparative study. As a guide to severity, it is much quicker than waiting for lab results to come in.

Despite hopes that rilonacept might provide a better alternative to NSAIDs or colchicines for gout pain, it does not provide significant relief either on its own or as an add-on therapy to indomethacin.

Does this evidence from recent research overturn some generally accepted principles about gout, rheumatoid arthritis, reactive arthritis, and osteoarthritis? Most of these studies were undertaken in order to test ideas that were described as common wisdom in rheumatology.


Subscribe to Gout on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.